Synthesis and biological evaluation of Complex I inhibitor R419 and its derivatives as anticancer agents in HepG2 cells
作者:Yaping Huang、Geng Sun、Pengfei Wang、Rui Shi、Yanchun Zhang、Xiaoan Wen、Hongbin Sun、Caiping Chen
DOI:10.1016/j.bmcl.2018.07.006
日期:2018.9
In this study, Complex I inhibitor R419 was firstly revealed to have significant anticancer activity against HepG2 cells (IC50 = 5.2 ± 0.9 μM). Based on this finding, a series of R419 derivatives were synthesized and biologically evaluated. As results, 9 derivatives were found to have obvious anticancer activity. Among them, H20 exhibited the most potent activity (IC50 = 2.8 ± 0.4 μM). Mechanism study
在这项研究中,首次发现复合物I抑制剂R419对HepG2细胞具有显着的抗癌活性(IC 50 = 5.2±0.9μM)。基于此发现,合成了一系列R419衍生物并对其进行了生物学评估。结果,发现9种衍生物具有明显的抗癌活性。其中,H20表现出最强的活性(IC 50 = 2.8±0.4μM)。机制研究表明,H20导致细胞ATP严重耗竭,剂量依赖性激活的AMPK,Bcl-2 / Bax比例降低并导致坏死性细胞死亡。最重要的是,H20对复合物I表现出明确的抑制活性。